Fluicell AB
Fluicell AB (publ) operates as a life science company, provides platforms and research solutions for bioprinting and single-cell biology. The company offers BIOPEN, a microfluidic platform for high-precision single-cell solution delivery that enables to control the cell microenvironment without moving or disturbing the cells; Biozone 6 that generate dose-response curves or study the effects of mu… Read more
Fluicell AB (FLUI) - Net Assets
Latest net assets as of September 2025: Skr10.80 Million SEK
Based on the latest financial reports, Fluicell AB (FLUI) has net assets worth Skr10.80 Million SEK as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr16.38 Million) and total liabilities (Skr5.58 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr10.80 Million |
| % of Total Assets | 65.93% |
| Annual Growth Rate | 32.11% |
| 5-Year Change | -1.35% |
| 10-Year Change | 2671.47% |
| Growth Volatility | 1313.9 |
Fluicell AB - Net Assets Trend (2014–2024)
This chart illustrates how Fluicell AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Fluicell AB (2014–2024)
The table below shows the annual net assets of Fluicell AB from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr19.23 Million | +4425.65% |
| 2023-12-31 | Skr425.00K | -98.19% |
| 2022-12-31 | Skr23.45 Million | +22.68% |
| 2021-12-31 | Skr19.11 Million | -1.98% |
| 2020-12-31 | Skr19.50 Million | +90.69% |
| 2019-12-31 | Skr10.22 Million | -56.25% |
| 2018-12-31 | Skr23.37 Million | +143.93% |
| 2017-12-31 | Skr9.58 Million | +420.48% |
| 2016-12-31 | Skr1.84 Million | +165.27% |
| 2015-12-31 | Skr694.00K | -41.54% |
| 2014-12-31 | Skr1.19 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Fluicell AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 15516705000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr38.46 Million | 199.98% |
| Other Comprehensive Income | Skr3.49 Million | 18.14% |
| Other Components | Skr134.71 Million | 700.37% |
| Total Equity | Skr19.23 Million | 100.00% |
Fluicell AB Competitors by Market Cap
The table below lists competitors of Fluicell AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
WindowMaster International AS
CO:WMA
|
$1.10 Million |
|
SANTIERUL NAVAL CONSTANTA S.A.
RO:SNC
|
$1.10 Million |
|
PRYME N.V EO -05
F:8XG
|
$1.10 Million |
|
Staffing 360 Solutions Inc
NASDAQ:STAF
|
$1.10 Million |
|
Venzee Technologies Inc
PINK:VENZF
|
$1.10 Million |
|
Kabelindo Murni Tbk
JK:KBLM
|
$1.09 Million |
|
Maris-Tech Ltd. Warrants
NASDAQ:MTEKW
|
$1.09 Million |
|
VHAI
BATS:VHAI
|
$1.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Fluicell AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 425,000 to 19,234,000, a change of 18,809,000 (4425.6%).
- Net loss of 15,511,000 reduced equity.
- Share repurchases of 39,514,000 reduced equity.
- New share issuances of 39,514,000 increased equity.
- Other comprehensive income increased equity by 3,490,000.
- Other factors increased equity by 30,830,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-15.51 Million | -80.64% |
| Share Repurchases | Skr39.51 Million | -205.44% |
| Share Issuances | Skr39.51 Million | +205.44% |
| Other Comprehensive Income | Skr3.49 Million | +18.14% |
| Other Changes | Skr30.83 Million | +160.29% |
| Total Change | Skr- | 4425.65% |
Book Value vs Market Value Analysis
This analysis compares Fluicell AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.76x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.36x to 0.76x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | Skr9.05 | Skr12.30 | x |
| 2015-12-31 | Skr5.29 | Skr12.30 | x |
| 2016-12-31 | Skr14.03 | Skr12.30 | x |
| 2017-12-31 | Skr46.00 | Skr12.30 | x |
| 2018-12-31 | Skr84.20 | Skr12.30 | x |
| 2019-12-31 | Skr34.15 | Skr12.30 | x |
| 2020-12-31 | Skr0.35 | Skr12.30 | x |
| 2021-12-31 | Skr0.32 | Skr12.30 | x |
| 2022-12-31 | Skr0.35 | Skr12.30 | x |
| 2023-12-31 | Skr0.41 | Skr12.30 | x |
| 2024-12-31 | Skr16.25 | Skr12.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Fluicell AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -80.64%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -834.37%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 1.33x
- Recent ROE (-80.64%) is above the historical average (-718.45%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -138.73% | -1174.10% | 0.08x | 1.41x | Skr-1.77 Million |
| 2015 | -545.16% | -267.23% | 0.83x | 2.46x | Skr-3.85 Million |
| 2016 | -268.88% | -187.86% | 0.95x | 1.51x | Skr-5.13 Million |
| 2017 | -77.96% | -710.08% | 0.09x | 1.20x | Skr-8.43 Million |
| 2018 | -62.89% | -1199.02% | 0.05x | 1.11x | Skr-17.04 Million |
| 2019 | -182.25% | -749.00% | 0.12x | 1.95x | Skr-19.66 Million |
| 2020 | -93.11% | -391.67% | 0.19x | 1.27x | Skr-20.10 Million |
| 2021 | -113.65% | -834.74% | 0.10x | 1.41x | Skr-23.63 Million |
| 2022 | -91.64% | -660.94% | 0.10x | 1.35x | Skr-23.83 Million |
| 2023 | -6248.00% | -795.51% | 0.36x | 21.98x | Skr-26.60 Million |
| 2024 | -80.64% | -834.37% | 0.07x | 1.33x | Skr-17.43 Million |
Industry Comparison
This section compares Fluicell AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,327,288
- Average return on equity (ROE) among peers: -132.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Fluicell AB (FLUI) | Skr10.80 Million | -138.73% | 0.52x | $1.10 Million |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |